title: The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD.
abstract: Alveolar macrophages in chronic obstructive pulmonary disease (COPD) have fundamentally impaired innate immune responses to toll-like receptor (TLR) ligands of nontypeable Haemophilus influenzae (NTHI). However, whether dysfunctional inflammatory responses in COPD extend to macrophage interactions with intact respiratory pathogens beyond NTHI has not been explored. Furthermore, the influences of exogenous factors, including active smoking and medications, on pathogen-induced innate immune responses have only begun to be investigated. We hypothesized that distinct alveolar macrophage impairments in COPD are not limited to NTHI TLR ligands and that active smoking and select COPD medications modulate innate responses. Alveolar macrophages, obtained from COPD ex-smokers (n = 32) and active smokers (n = 64) by bronchoalveolar lavage (BAL), were incubated with NTHI, Moraxella catarrhalis, and Streptococcus pneumoniae, and with TLR2 and TLR4 ligands. Elicited IL-8 and TNF-α were measured by multianalyte microsphere flow cytometry to determine proinflammatory responsiveness. Induced IL-8, but not TNF-α, was greater from alveolar macrophages of active smokers compared with ex-smokers, in response to NTHI (p = 0.04), M. catarrhalis (p = 0.003), and S. pneumoniae (p = 0.03). Both IL-8 and TNF-α induction by TLR2 and TLR4 ligands were greater in active smokers. While intergroup NTHI- and M. catarrhalis-induced TNF-α levels were no different, they were notably lower among ex-smokers taking anticholinergic medications (p < 0.04 for each), but not with any other bronchoactive medications. Our results support a paradigm of distinct immunologic responses of COPD alveolar macrophages of ex- and active smokers to diverse respiratory pathogens and highlight a subset of ex-smokers whose diminished alveolar macrophage responsiveness may be associated with anticholinergic agents.
authors: a Divisions of Infectious Diseases and Pulmonary, Critical Care, Sleep, Department of Veterans Affairs , Western New York Healthcare System, State University of New York at Buffalo School of Medicine , Buffalo , NY , USA.
authors: Charles S
authors: CS
authors: Berenson
authors: a Divisions of Infectious Diseases and Pulmonary, Critical Care, Sleep, Department of Veterans Affairs , Western New York Healthcare System, State University of New York at Buffalo School of Medicine , Buffalo , NY , USA.
authors: Ragina L
authors: RL
authors: Kruzel
authors: a Divisions of Infectious Diseases and Pulmonary, Critical Care, Sleep, Department of Veterans Affairs , Western New York Healthcare System, State University of New York at Buffalo School of Medicine , Buffalo , NY , USA.
authors: Sanjay
authors: S
authors: Sethi
mesh_terms: D000368:Aged; D018680:Cholinergic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D005260:Female; D054884:Host-Pathogen Interactions / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D008024:Ligands; D016676:Macrophages, Alveolar / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism*; D012307:Risk Factors; D051193:Toll-Like Receptors / Q000378:metabolism
chemical_list: D018680:Cholinergic Antagonists; D016207:Cytokines; D008024:Ligands; D051193:Toll-Like Receptors
keywords: Alveolar macrophage; COPD; anticholinergic; cytokine